Ranbaxy will launch botulinum toxin derived anti-ageing drug Neuronox from Medi-Tox Inc in India.
Ranbaxy Laboratories Ltd entered into an in-licensing agreement with South Korean firm Medy-Tox Inc for selling a cosmetic product Neuronox in India.
Neuronox is Medi-Tox’s new alternative brand of purified botulinum toxin type –A.
Neuronox is considered one of the effective ant-aging medicine derived from botulin toxin. The cosmetic use of botulinum toxin type- A in the correction of facial wrinkles and excessive sweating (hyperhidrosis), has rapidly become one of the most popular cosmetic procedures worldwide.
Therapeutic equivalence and clinical trials conducted by Medy-Tox in various countries across the world, have confirmed the efficacy and safety of Neuronox, Ranbaxy said in a press release.
MD.AZEEM PARVEZ
PGDM-III
SEC-A
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment